SANGUINE

Project Duration: January 2023 to January 2026

Each year, about 300,000 Europeans are diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma - each placing unique demands on health systems. This Blood Cancer Awareness Month, SANGUINE’s Stakeholder Forum Report captures key discussions, expert quotes, and concrete policy recommendations to advance innovation in blood cancer detection.

Discover the report!

About SANGUINE

The Project SANGUINE addresses the objectives raised by the Cancer Mission Call, which emerged from the growing societal challenge faced by European citizens. According to the European Cancer Information System (ECIS), each year, 2.7 million people in the EU are diagnosed with cancer. The SANGUINE project focuses on hematological malignancies, which account for 10% of those cases.

The 36 month project, led by Tel Aviv University (TAU), introduces a novel minimally-invasive blood test that detects and classifies a set of hematological malignancies. The test is based on detecting a combination of epigenetic biomarkers in DNA from peripheral blood cells and in cell-free DNA.

ECO is leading Work Package 6 on dissemination, communication, exploitation and patients engagement. The objectives of the Work Package is to ensure the uptake, diffusion, deployment, and/or use of the project’s results by direct target groups through the creation and implementation of a dissemination, exploitation and communication plan.

This project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement Nº 101097026.